Significant advances were presented in individualized neoantigen vaccines, with TG4050 progressing in head and neck cancer and TG4070 launching in non-small cell lung cancer. Manufacturing is transitioning to a scalable cell line process, and the SNIPER platform is validated for future indications. Expansion into Monkeypox/Smallpox vaccines leverages these innovations.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.